Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”


HHS - 1483 - National Cancer Institute Board of Scientific Advisors - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Institute Board of Scientific AdvisorsAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number1483
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*35
Current Charter Date10/8/2021Designated Fed Officer Position Title*DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Date Of Renewal Charter10/8/2023Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*PAULETTE
Exempt From Renewal*NoDesignated Federal Officer Middle NameS.
Specific Termination AuthorityDesignated Federal Officer Last Name*GRAY
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPH.D.
Specific Establishment Authority*42 U.S.C. 285a-2(b)(7)Designated Federal Officer Phone*240-276-6340
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-276-7815
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*grayp@mail.nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Board is composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considers meritorious and consistent with the Institute’s programs. The advisory role of the Board is scientific and does not include deliberation on matters of public policy. In FY2022, the BSA was presented reports on various topics related to cancer research in general as well as legislative matters. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control) (New RFA/Coop. Agr.); Cancer Control Research in Persistent Poverty Areas (New RFA/Coop. Agr.); Pediatric Immunotherapy Network (PIN) (New RFA/Coop. Agr.); Integrating Health Disparities into Immuno-Oncology Research (HDIO) (New RFA); A Data Resource for Analyzing and Supporting Blood and Marrow Transplants and Cellular Immunotherapy Research Center for International Blood and Marrow Transplant Research (CIBMTR) (Re-Issue RFA/Coop. Agr.); Patient-Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network (U54) and PDX Data Commons and Coordinating Center (PDCCC) for PDXNet (Re-Issue RFA); Informatics Technology for Cancer Research (Re-Issue RFA/Coop. Agr.); Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (Re-Issue RFA/Coop. Agr.); Consortium on Translational Research in Early Detection of Liver Cancer (TLC) (Re-Issue RFA/Coop. Agr.); Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (New RFA); Outstanding Investigator Award (R35) (New RFA); Cancer Adoptive Cellular Therapy Network (Can-ACT) (New RFA/Coop. Agr.); Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) Network (Re-Issue RFA/Coop. Agr.); Basic/Translational Research on Health Disparities in HIV/AIDS and Cancer (New RFA); Advancing Adolescent Tobacco Cessation Intervention Research (New RFA); Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (New RFA); Cancer Screening Research Network (CSRN) to Evaluate Multi-Cancer Early Detection Assays for Clinical Utility in Cancer Screening (New RFA); Transformative Educational Advancement and Mentoring Network (TEAM) (New RFA); and Cancer Moonshot Scholars Diversity Program (New RFA).
How is membership balanced?*The Board consists of up to 35 members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations are addressed in selecting members for appointment to the Board.
How frequent & relevant are cmte mtgs?*Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the virtual December 2021 and virtual June 2022 meetings. The Board also met virtually in March 2022. The Board’s deliberations are an indispensable part of the review of a very large part of the Institute’s extramural program, as well as concept review of request for applications (RFAs), program announcements with special receipt, referral, and review (PARs), and research and development (R&D) requests for proposals (RFP) contract initiatives in the extramural research program. According to the Board’s charter, approximately three formal meetings are held each year for the review of the extramural programs and concept review of RFAs; cooperative agreements; and, research and development RFPs.
Why advice can't be obtained elsewhere?*This Board is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluations of extramural research programs. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.
Why close or partially close meetings?N/A
Recommendation RemarksVacancies/Members On-Boarding: The Board currently has six vacancies, and fourteen members were on-boarded: Chandraknath Are, Suzanne Baker, Karen Basen-Engquist, Andrew Chan, Nelson Chao, Gloria Coronado, Chyke Doubeni, Henry Earp, Jennifer Grandis, Dorothy Hatsukami, Trey Idekar, Karen Mustian, Erle Robertson, and Richard Zellars. This is why the Charter states 35 potential members, but this ACR lists 29.

Members: The terms for Michael Becich, Mary Beckerle, Melissa Bondy, Sylvia Plevritis, Leslie Robison, Robert Schreiber, David Sidransky, Ian Thompson, David Tuveson, and Robert Vonderheide have changed due to administrative extensions. As such, their terms of service end dates are different than what was reported on the FY21 ACR. The term for Michael Becich is longer than the Charter allows due to their reappointment to the BSA given their specific scientific expertise and the need to assure continuity in the functions of the BSA and the deliberation of issues brought before the Board.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

Reports: This committee did not produce any public reports.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentNoAction Reallocate ResourcesYes
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentPriorities are reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources are allocated based on approved concepts.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherYesNumber Of Grants Reviewed0
Outcome CommentBased on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, and behavioral modifications and cures for different cancer sites. Another outcome is the annual posting of the RFA Report.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentMeetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the virtual December 2021 and virtual June 2022 meetings. The Board also met virtually in March 2022. Additionally, RFA and RFP concepts are reviewed annually to determine the need for reissuance based on the Board recommendations. Ad hoc Subcommittee and/or working group meetings are held to gather information. Recommendations are reported back at a full board meeting where advice is given to the Institute. The BSA supports the Institute in meeting its mission and as a result even though it can’t be calculated, there are substantive savings.Grants Review CommentNA
Number Of Recommendations*472Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentIn addition to general recommendations, specific recommendations by the committee include: 1. A motion to approve the Office of the Director’s (OD) new Request for Applications (RFA) /Cooperative Agreement (Coop. Agr.) entitled “Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control)” was approved unanimously. 2. A motion to concur on the re-issuance of the Division of Cancer Prevention’s (DCP) Request for Proposals (RFP) entitled “PREVENT Cancer Preclinical Drug Development Program” was approved unanimously. 3. A motion to approve the Division of Cancer Control and Population Sciences’ (DCCPS) new Program Announcement with special Receipt, Referral, and/or Review (PAR) entitled “Cancer Epidemiology Cohorts: Research Opportunities in Established Studies” was approved unanimously. 4. A motion to approve the DCCPS’ new PAR entitled “Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (Clinical Trials Not Allowed)” was approved unanimously. 5. A motion to approve the DCCPS’ new RFA/Coop. Agr. entitled “Cancer Control Research in Persistent Poverty Areas” was approved unanimously. 6. A motion to approve the Division of Cancer Treatment and Diagnosis’ (DCTD)/Division of Cancer Biology’s (DCB) new RFA/Coop. Agr. entitled “Pediatric Immunotherapy Network (PIN)” was approved unanimously. 7. A motion to approve DCB’s/OD’s new RFA entitled “Integrating Health Disparities into Immuno-Oncology Research (HDIO)” was approved unanimously. 8. A motion to concur on re-issuance of the DCTD’s RFA/Coop. Agr. entitled “A Data Resource for Analyzing and Supporting Blood and Marrow Transplants and Cellular Immunotherapy Research Center for International Blood and Marrow Transplant Research (CIBMTR)” was approved unanimously. 9. A motion to concur on re-issuance of the DCTD’s/OD’s RFA entitled “Patient-Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network (U54) and PDX Data Commons and Coordinating Center (PDCCC) for PDXNet” was approved unanimously. 10. A motion to approve the DCTD’s new PAR entitled “Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) was approved with 12 ayes, 0 nays, and 1 abstention. 11. A motion to concur on re-issuance of the OD’s RFA/Coop. Agr. entitled “Informatics Technology for Cancer Research” was approved unanimously. 12. A motion to concur on the re-issuance of the DCP’s RFA/Coop. Agr. entitled “Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment” was approved with 25 ayes, zero nays, and 1 abstention. 13. A motion to concur on the re-issuance of the DCP’s RFA/Coop. Agr. entitled “Consortium on Translational Research in Early Detection of Liver Cancer (TLC)” was approved with 25 ayes, zero nays, and 1 abstention. 14. A motion to approve the DCCPS’ new RFA entitled “Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer” was approved unanimously. 15. A motion to approve the DCCPS’ new PAR entitled “Pragmatic Trials across the Cancer Control Continuum” was approved unanimously. 16. A motion to approve the OD’s new RFA entitled “Outstanding Investigator Award (R35)” was approved unanimously. 17. A motion to approve the DCTD’s new PAR entitled “Precision Approaches in Radiation Synthetic combinations (PAIRS)” was approved unanimously. 18. A motion to approve the DCTD’s new RFA/Coop. Agr. entitled “Cancer Adoptive Cellular Therapy Network (Can-ACT)” was approved unanimously. 19. A motion to concur on the re-issuance of the DCTD’s RFA/Coop. Agr. entitled “Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) Network” was approved with 23 ayes, zero nays, and 3 abstentions. 20. A motion to approve the OD’s RFP entitled “Small Business Innovation Research (SBIR) Contract Topics” was approved unanimously. 21. A motion to approve the DCB’s new PAR entitled “The Metastasis Research Network (MetNet): MetNet Research Projects” was approved unanimously. 22. A motion to approve the DCB’s new RFA entitled “Basic/Translational Research on Health Disparities in HIV/AIDS and Cancer” was approved unanimously. 23. A motion to approve the DCB’s new PAR entitled “Mechanistic Links Between Diet, Lipid Metabolism, and Tumor Growth and Progression” was approved unanimously. 24. A motion to approve the DCCPS’ new RFA entitled “Advancing Adolescent Tobacco Cessation Intervention Research” was approved unanimously. 25. A motion to approve the DCCPS’ new RFA entitled “Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms” was approved unanimously. 26. A motion to approve the DCP’s new RFA entitled “Cancer Screening Research Network (CSRN) to Evaluate Multi-Cancer Early Detection Assays for Clinical Utility in Cancer Screening” was approved unanimously. 27. A motion to approve the OD’s new RFA entitled “Transformative Educational Advancement and Mentoring Network (TEAM)” was approved unanimously. 28. A motion to approve the OD’s new RFA entitled “Cancer Moonshot Scholars Diversity Program” was approved unanimously. 29. A motion to concur on nine PAR re-issuances was approved unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*90.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.govAccess GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the BSA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the BSA meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback Comment*The NCI Director’s Report is presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report is presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items are assigned to individual NCI staff with specific time frames with deadlines.
Information is provided to the public at each meeting. The public can view information related to the Board through the BSA official website.
Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor’s (BSA). The BSA is composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA is scientific and does not include deliberation on matters of public policy. The BSA represents the scientific community's voice in the extramural science the NCI supports. As such, the Board advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs, and reviews ideas for new research opportunities and solicitations to ensure that a concept is meritorious and consistent with the Institute's mission. Additionally, the BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA’s deliberations are an indispensable part of the review of a very large part of the Institute's extramural program.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$33,400.00Est Payments to Non-Fed Members Next FY*$33,400.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$75,344.00Estimated Payments to Federal Staff*$77,378.00
Payments to Consultants*$4,000.00Est. Payments to Consultants Next FY*$4,000.00
Travel Reimb. For Non-Federal Members*$542.00Est Travel Reimb Non-Fed Members nextFY*$67,250.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$21,634.00
Other Costs$34,521.00Est. Other Costs Next FY*$35,366.00
Total Costs$147,807.00Est. Total Next FY*$239,028.00
Date Cost Last Modified10/3/2022 12:03 PMEst. Fed Staff Support Next FY*0.40
Federal Staff Support (FTE)*0.40Est Cost RemarksProjected costs for FY23 were increased in the event that in-person/hybrid meetings resume.
Cost RemarksMeetings were held virtually in FY22 due to the ongoing COVID-19 pandemic as such the FY22 Operating Costs are lower than what was projected on the FY21 FOP. The travel cost reported for FY22 was for a BSA member to attend a FNLAC Working Group hybrid meeting.  
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Treatment
Medicine
Diseases
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-040420National Cancer Institute Board of Scientific Advisors2021
 COM-038695National Cancer Institute Board of Scientific Advisors2020
 COM-036569National Cancer Institute Board of Scientific Advisors2019
 COM-034777National Cancer Institute Board of Scientific Advisors2018
 COM-001923National Cancer Institute Board of Scientific Advisors2017
 COM-002258National Cancer Institute Board of Scientific Advisors2016
 COM-004079National Cancer Institute Board of Scientific Advisors2015
 COM-004408National Cancer Institute Board of Scientific Advisors2014
 COM-006156National Cancer Institute Board of Scientific Advisors2013
 COM-006867National Cancer Institute Board of Scientific Advisors2012
 COM-008324National Cancer Institute Board of Scientific Advisors2011
 COM-009069National Cancer Institute Board of Scientific Advisors2010
 COM-010116National Cancer Institute Board of Scientific Advisors2009
 COM-011002National Cancer Institute Board of Scientific Advisors2008
 COM-012119National Cancer Institute Board of Scientific Advisors2007
 COM-012487National Cancer Institute Board of Scientific Advisors2006
 COM-013962National Cancer Institute Board of Scientific Advisors2005
 COM-014543National Cancer Institute Board of Scientific Advisors2004
 COM-016033National Cancer Institute Board of Scientific Advisors2003
 COM-016593National Cancer Institute Board of Scientific Advisors2002
 COM-017634National Cancer Institute Board of Scientific Advisors2001
 COM-018354National Cancer Institute Board of Scientific Advisors2000
 COM-019571National Cancer Institute Board of Scientific Advisors1999
 COM-020365National Cancer Institute Board of Scientific Advisors1998
 COM-021711National Cancer Institute Board of Scientific Advisors1997